423 related articles for article (PubMed ID: 30343607)
1. Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis.
Kashyap A; Singh PK; Silakari O
Drug Metab Rev; 2018 Nov; 50(4):448-465. PubMed ID: 30343607
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview.
Silva C; Perdigão J; Jordão L; Portugal I
Int J Antimicrob Agents; 2014 Dec; 44(6):546-51. PubMed ID: 25270633
[TBL] [Abstract][Full Text] [Related]
3. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps.
Amaral L; Martins M; Viveiros M; Molnar J; Kristiansen JE
Curr Drug Targets; 2008 Sep; 9(9):816-9. PubMed ID: 18781927
[TBL] [Abstract][Full Text] [Related]
4. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB.
Martins M
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742
[TBL] [Abstract][Full Text] [Related]
5. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
6. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
8. RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in South Korea.
Oh TS; Kim YJ; Kang HY; Kim CK; Cho SY; Lee HJ
Infect Genet Evol; 2017 Apr; 49():111-115. PubMed ID: 28062386
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012.
Yin QQ; Jiao WW; Li QJ; Xu F; Li JQ; Sun L; Li YJ; Huang HR; Shen AD
BMC Microbiol; 2016 May; 16():85. PubMed ID: 27176471
[TBL] [Abstract][Full Text] [Related]
10. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
[TBL] [Abstract][Full Text] [Related]
11. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
12. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
13. Nanocarrier-based interventions for the management of MDR/XDR-TB.
Mustafa S; Pai RS; Singh G; Kusum Devi V
J Drug Target; 2015 May; 23(4):287-304. PubMed ID: 25766078
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of drug resistance in Mycobacterium tuberculosis.
Zhang Y; Yew WW
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1320-30. PubMed ID: 19861002
[TBL] [Abstract][Full Text] [Related]
15. It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.
Amaral L
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):76. PubMed ID: 21796848
[No Abstract] [Full Text] [Related]
16. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
Lee H; Suh JW
J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
[TBL] [Abstract][Full Text] [Related]
17. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
[TBL] [Abstract][Full Text] [Related]
18. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
19. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.
Streicher EM; Müller B; Chihota V; Mlambo C; Tait M; Pillay M; Trollip A; Hoek KG; Sirgel FA; Gey van Pittius NC; van Helden PD; Victor TC; Warren RM
Infect Genet Evol; 2012 Jun; 12(4):686-94. PubMed ID: 21839855
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
